Appili Therapeutics Inc. (OTCMKTS:APLIF) Sees Large Increase in Short Interest

Appili Therapeutics Inc. (OTCMKTS:APLIF) saw a significant increase in short interest in the month of June. As of June 15th, there was short interest totaling 25 shares, an increase of ∞ from the May 31st total of 0 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average daily volume of 8,277 shares, the short-interest ratio is currently 0.0 days.

Appili Therapeutics Trading Down 2.7%

Shares of Appili Therapeutics stock opened at $0.01 on Wednesday. The firm has a market capitalization of $1.46 million, a P/E ratio of -0.27 and a beta of -0.06. The business has a fifty day simple moving average of $0.01 and a two-hundred day simple moving average of $0.01. Appili Therapeutics has a 12 month low of $0.01 and a 12 month high of $0.03.

Appili Therapeutics (OTCMKTS:APLIF) last released its earnings results on Friday, June 26th. The company reported $999.00 earnings per share for the quarter. The business had revenue of $0.03 million during the quarter.

Appili Therapeutics Company Profile

Appili Therapeutics Inc is a clinical-stage pharmaceutical company headquartered in Vancouver, Canada. The company specializes in the development and commercialization of novel anti-infective therapies designed to address both endemic and emerging infectious disease threats. Appili’s strategic focus includes small-molecule antibiotics, antivirals and vaccine adjuvants, with an emphasis on formulations suitable for rapid deployment in resource-limited or outbreak settings.

Appili’s product pipeline features multiple candidates in various stages of development.